Nociceptor-Specific Gene Regulatory Elements for Selective Pain Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic pain, such as using non-specific anesthetics, are short-lived and inhibit all peripheral sensory neurons, leading to undesirable side effects, while targeted gene therapies for nociceptors are needed to selectively silence pain pathways without affecting other sensory functions.
Innovation Solution
Engineered and naturally occurring gene regulatory elements (GREs) are used to drive the expression of specific proteins in peptidergic and non-peptidergic nociceptors, enabling selective expression of therapeutic proteins like analgesic peptides within the dorsal root ganglion, using adeno-associated virus (AAV) vectors to target nociceptors specifically.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific anesthetics are used to silence nociceptor activity, then pain relief is achieved, but all peripheral sensory neurons are inhibited leading to loss of other sensory functions
Solution Approach 1:
The patent applies local quality by using nociceptor-specific gene regulatory elements (such as promoter regions from TAC1, SCN9A, or SCN10A genes) that drive transgene expression exclusively in nociceptive neurons. This ensures that therapeutic proteins are produced only in pain-sensing cells while leaving other sensory neuron populations untouched, thereby achieving pain relief without compromising touch, temperature, or other non-painful sensory functions.
2Reliability
If non-specific anesthetics are used for pain treatment, then pain relief is provided, but the treatment duration is short-lived
Solution Approach 1:
The patent employs gene therapy vectors (such as AAV or lentiviral vectors) that deliver genetic material encoding therapeutic proteins directly to nociceptors. Once the transgene is integrated into the nociceptor genome, it continuously produces the therapeutic protein over extended periods (months to years), eliminating the need for repeated administrations and providing long-lasting pain relief compared to transient anesthetic effects.
3Object-affected harmful factors
If targeted gene therapy is used to selectively express transgene in nociceptors, then specificity and safety are improved, but the complexity of the therapy increases
Solution Approach 1:
The patent utilizes gene regulatory elements (promoters, enhancers, and other cis-regulatory sequences) as intermediaries to mediate between the transgene and nociceptor-specific expression. These regulatory elements act as molecular switches that recognize and bind transcription factors present in nociceptors, thereby directing transgene expression specifically to these cells without requiring complex targeting mechanisms or multiple delivery systems.
Data Source
AI summary
Aspects of the disclosure provide nucleic acids and compositions comprising gene regulatory elements (GREs) for specific expression in nociceptor cells. Other aspects of the disclosure relate to the use of vectors and compositions comprising the gene regulatory elements for treating or managing pain and other neurological diseases in a subject in need thereof.